Table 1 Baseline characteristics of patients on somatostatin analogue treatment for metastatic disease from small-intestinal neuroendocrine tumour

Males,n(%)

47 (53.4%)

Age, median (range)

65.0 (32–87) years

Time since diagnosis, median (range)

4.82 (0.3–34.3) years

Time since first treatment, median (range)

3.09 (0.2–15.3) years

Weight, median (range)

72.5 (40–130) kg

70.0 (40–132) kg

Weight change from baseline, median (range)

0.0 (−15–13) kg

None

61 (69.3%)

51 (67.1%)^b

0–5%

18 (20.5%)

17 (22.4%)^b

6–10%

7 (8.0%)

6 (7.9%)^b

> 10%

2 (2.3%)

2 (2.6%)^b

Retired

53 (60.2%)

50 (66.7%)^b

Non-retired

35 (39.8%)

25 (33.3%)^b

Working (% of non-retired)

15 (42.9%)

12 (48.0%)^b

Not working (% of non-retired)

20 (57.1%)

13 (52.0%)^b

Metastatic mesenteric lymph nodes

34 (38.6%)

Other metastatic lymph nodes

35 (39.8%)

Liver metastases

78 (88.8%)

Lung metastases

1 (1.1%)

Other metastases

23 (26.1%)

Surgery of primary tumour,n(%)

74 (84.1%)

Surgery of mesenteric lymph nodes

42 (49.4%)^b

Surgery of liver metastases

14 (17.1%)^b

Ki67, median (min-max)

1.0% (1–15%)

0–2%

60 (68.2%)

> 2%

28 (31.8%)

0

49 (55.7%)

48 (62.3%)

1

31 (35.2%)

16 (20.8%)

2

7 (8.0%)

11 (14.3%)

3

1 (1.1%)

2 (2.6%)

Smoker,n(%)

11 (12.6%)^b

Interferon

22 (25.0%)

4 (5.2%)^c

PRRT

21 (23.9%)

19 (24.7%)^c

5-HIAA in urine, above normal,n(%)

42 (79.2%)^b

25 (83.3%)^b

CgA in blood, above normal,n(%)

64 (72.7%)

55 (75.3%)^b

Current use

26 (29.5%)

27 (35.5%)^b

Prior and current use

39 (44.3%)

NA

Current use

20 (22.7%)

17 (22.4%)^b

Prior and current use

38 (43.2%)

NA

Current use

6 (6.8%)

6 (7.9%)^b

Prior and current use

13 (14.8%)

NA

Current use

59 (67.0%)

64 (83.1%)